Clinical Trials

Phase 1/2 Active not recruiting

Pancreatic Neoplasms

NCT04708470 2026-04-06

A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers

55 enrolled

GastrointestinalGenitourinaryGynecologicHead & Neck

Anus Neoplasms, Uterine Cervical Neoplasms, Colonic Neoplasms, Head and Neck Neoplasms, Oropharyngeal Neoplasms, Penile Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms

NCT07492394 2026-04-02

Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer

Phase 2 Recruiting

60 enrolled

Breast Neoplasms

NCT03211988 2026-03-02

Entinostat Neuroendocrine (NE) Tumor

Phase 2 Not yet recruiting

5 enrolled 9 charts

EndocrineNET

Recurrence, Neuroendocrine Tumors

NCT07441486 2026-03-02

A Single-arm, Prospective, Phase II Clinical Study of the Combination of Entinostat and Oral Paclitaxel in the Treatment of HR+HER2- Advanced Breast Cancer

50 enrolled

Breast Neoplasms

NCT07330544 2026-01-09

A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy

Phase 2 Recruiting

118 enrolled

Phase 3 Active not recruiting

Breast Neoplasms

NCT02115282 2025-12-18

Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

608 enrolled 18 charts

Phase 1/2 Not yet recruiting

Breast Neoplasms

NCT07261592 2025-12-03

Entinostat & Chemotherapy for Locally Advanced or Metastatic Bladder Cancer

29 enrolled

Phase 2 Not yet recruiting

Urinary Bladder Neoplasms

NCT07235618 2025-11-19

A Study of Entinostat in Combination With Fulvestrant for the Treatment of Locally Advanced or Metastatic Breast Cancer

50 enrolled

Breast Neoplasms

NCT03280563 2025-11-10

MORPHEUS HR+BC

144 enrolled 25 charts

Phase 2 Active not recruiting

Breast Neoplasms

NCT03978624 2025-10-15

Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer

20 enrolled 11 charts

Urinary Bladder Neoplasms

NCT04631029 2025-10-03

Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread

Phase 2 Active not recruiting

3 enrolled 12 charts

CNS

Brain Neoplasms

NCT03179930 2025-07-23

Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas

47 enrolled

Lymphoid

Lymphoma, Recurrence

NCT03250273 2025-05-28

A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma

44 enrolled 19 charts

Neoplasm Metastasis, Pancreatic Neoplasms, Cholangiocarcinoma

NCT01349959 2025-04-27

Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer

58 enrolled 16 charts

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT02437136 2025-03-20

Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC)

191 enrolled 26 charts

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

NCT03024437 2025-03-20

Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma

Phase 1/2 Terminated

31 enrolled 19 charts

Kidney Neoplasms, Neoplasm Metastasis

NCT02708680 2024-12-04

Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In

89 enrolled 16 charts

Breast Neoplasms

NCT03552380 2024-09-03

Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma

12 enrolled 16 charts

Carcinoma, Renal Cell

NCT05898828 2024-08-05

Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer

Phase 1/2 Withdrawn

Esophageal Neoplasms, Neoplasms

NCT01928576 2024-05-03

NA_00084192

Phase EARLY_PHASE1 Terminated

143 enrolled 13 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03361800 2024-03-25

Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC

5 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03838042 2024-02-07

INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies

Phase 1/2 Recruiting

91 enrolled

CNS

Central Nervous System Neoplasms

NCT02915523 2024-01-10

Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer

140 enrolled 25 charts

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Diseases, Ovarian Neoplasms

NCT03765229 2024-01-10

An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV Melanoma

11 enrolled 12 charts

Dermatologic

Melanoma

NCT02697630 2023-12-08

PEMDAC

29 enrolled

Dermatologic

Uveal Melanoma

NCT03215264 2023-11-09

To Determine the Safety of Regorafenib, Hydroxychloroquine, and Entinostat Metastatic Colorectal Cancer

20 enrolled 9 charts

Colorectal Neoplasms

NCT02780804 2023-10-17

Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

Phase 2 Active not recruiting

21 enrolled 15 charts

CNSLymphoid

Lymphoma, Pinealoma, Central Nervous System Neoplasms, Brain Stem Neoplasms

NCT03501381 2023-09-01

High Dose IL 2 and Entinostat in RCC

46 enrolled

Carcinoma, Renal Cell

NCT00750698 2023-07-06

A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib

8 enrolled 6 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03473639 2022-11-01

Breast49

13 enrolled

Breast Neoplasms

NCT00602030 2022-08-22

Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC

141 enrolled 24 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00828854 2022-06-30

Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing

27 enrolled 13 charts

Breast Neoplasms

NCT02623751 2022-06-21

Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer

15 enrolled

Breast Neoplasms

NCT03291886 2022-06-21

Phase 2 Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer

133 enrolled

Breast Neoplasms

NCT00754312 2022-06-06

A Phase I, Multicenter, Open Label Study on the Effects of SNDX-275 on Expression of Biomarkers in Subjects With Newly Diagnosed Breast Cancer

1 enrolled

Breast Neoplasms

NCT00676663 2022-05-11

ENCORE301

130 enrolled 18 charts

Breast Neoplasms, Mammary Neoplasms, Animal

NCT01234532 2022-05-03

0927GCC

5 enrolled 7 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02897778 2022-04-28

Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors

BreastGastrointestinalGenitourinaryThoracic

30 enrolled

Breast Diseases, Breast Neoplasms, Bronchial Neoplasms, Carcinoma, Non-Small-Cell Lung, Digestive System Neoplasms, Endocrine Gland Neoplasms, Kidney Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT03924245 2022-04-04

Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers

3 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT02909452 2022-01-25

Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

BreastGastrointestinalGenitourinaryThoracic

30 enrolled

Breast Diseases, Bronchial Neoplasms, Carcinoma, Non-Small-Cell Lung, Digestive System Neoplasms, Endocrine Gland Neoplasms, Kidney Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT04296942 2022-01-11

BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)

1 enrolled 10 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02820961 2021-12-15

Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer

61 enrolled

Breast Diseases, Breast Neoplasms

NCT01594398 2021-11-19

ENCORE110

Phase EARLY_PHASE1 Completed

14 enrolled

BreastThoracic

Breast Diseases, Breast Neoplasms, Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT03018249 2021-11-16

Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer

50 enrolled 12 charts

Gynecologic

FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma

NCT03829930 2021-08-02

Combination of Entinostat and Enzalutamide in Advanced Prostate Cancer

6 enrolled

Prostate Adenocarcinoma

NCT03538171 2021-07-09

Ph3 Study of Exemestane With or Without Entinostat in Chinese Patients With Hormone Receptor-Positive, Locally Advanced or Metastatic Breast Cancer

Phase 3 Unknown

375 enrolled

Advanced Breast Cancer

NCT03760614 2021-01-15

A Study of Entinostat and FOLFOX in Subjects With Pancreatic Adenocarcinoma

Phase 1 Withdrawn